Industry Research

71. How Prevalent Are PPAs In Phase 2/3 Research? 5/1/2019

    Almost half of survey respondents report their companies use formal preferred provider agreements (PPAs) for their Phase 2/3 outsourcing.

72. Are Outsourcers Interested In Changing Their CRO Mix? 4/1/2019

    ISR recently surveyed decision makers across all phases of clinical development to gain insight on sponsor/CRO dynamics. More than half of respondents agreed (to some level)that their organization would change its mix of CROs.

73. A Look At 2018's CDMO Expansions 12/3/2018

    ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.

74. The Interconnected World Of Blockbuster Oncology Drugs 11/7/2018

    A hypertree showing the network of connections between 2017’s top-selling oncology products. Oncology drugs made up 13 of last year’s top 50 selling products.

75. The Top 5 Selection Drivers For Phase IV Services 10/4/2018

    Understanding which attributes industry peers feel are important can help in the process of CRO selection.

76. Department Influence On CMO Selection 9/3/2018

    When it comes to CMO selection, Executive Management and Manufacturing/Production hold the most influence over the decision, each accounting for ~20% of control.

77. Choosing A Development-Stage eCOA/ePRO Provider 8/2/2018

    ISR asked study sponsors, CROs, and clinical research sites what’s the most important attribute they would use to select an eCOA (electronic clinical outcomes assessment)/ePRO (electronic patient reported outcomes) provider for development-stage products.

78. What Are The Largest Slices Of The 2018 CRO Market? 7/5/2018

    2017 was another strong year for CRO growth, with all major/public service providers experiencing year-over-year revenue gains. The largest component of CRO market revenue by geography, development, and service line is highlighted here.

79. Is The U.S. Biosimilar Industry Falling Behind? 6/1/2018

    Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.

80. Trial Data Collection: Paper Vs. Electronic 5/2/2018

    The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.